苏黄止咳胶囊联合沙美特罗/丙酸氟替卡松治疗咳嗽变异性哮喘的临床观察

Abstract
Figure/Table
References (25)
Related Citation (15)

Download: PDF (470 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the clinical effect of Suhuang Cough Capsules combined with Salmeterol/Fluticasone Propionate in the treatment of cough variant asthma (CVA). Methods Sixty patients diagnosed with CVA from December 2015 to August 2017 in First People′s Hospital of Huzhou were selected and randomly divided into two groups, with 30 cases in each group. Patients in the observation group were treated with Salmeterol 50 μg/Fluticasone Propionate 250 μg inhalation combined with Suhuang Cough Capsules. Patients in the control group were treated with Salmeterol 50 μg/Fluticasone Propionate 250 μg inhalation, both groups were treated for 4 weeks. After two weeks of continuous drug treatment, the cough symptom score was observed in both groups. After 4 weeks, patients of the two groups were evaluated by the asthma control test (ACT) questionnaire, and the levels of total serum IgE, TNF-α, IL-4 and IL-6 were measured and the percentage of sputum eosinophils was induced. Results The total efficiency of the observation group (93.33%) was higher than that of the control group (73.33%), the difference was statistically significant (P ＜ 0.05). After treatment, the scores of both groups were significantly lower than those before treatment, and the observation group was significantly lower than the control group (P ＜ 0.05). The ACT score of the observation group was significantly higher than that of the control group, and the difference was statistically significant (P ＜ 0.05). After treatment, the sputum eosinophil percentage, serum IgE, TNF-α levels in two groups were lower than those before treatment (P ＜ 0.05), and the observation group was significantly lower than the control group (P ＜ 0.05). Conclusion Suhuang Cough Capsules combined with Salmeterol/Fluticasone Propionate can reduce the level of serum IgE, TNF-α and the sputum eosinophil percentage in adult patients with cough variant asthma, reduce airway inflammation and improve cough symptoms, so as to improve the therapeutic effect.

Key words： Suhuang Cough Capsules Salmeterol/Fluticasone Propionate Cough variant asthma Curative effect

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHEN Huifen XIE Yanping FU Huanqin YAO Wei

Cite this article:

CHEN Huifen XIE Yanping FU Huanqin YAO Wei. The clinical observation of Suhuang Cough Capsules combined with Salmeterol/Fluticasone Propionate in the treatment of cough variant asthma[J]. 中国医药导报, 2018, 15(9): 105-108.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2018/V15/I9/105

[1] Song WJ，Kang MG，Chang YS，et al. Epidemiology of adul?鄄tasthma in Asia：toward a better understanding [J]. Asia Pac Allergy，2014，4（2）：75-85.
[2] 苏楠，林江涛，刘国梁，等.我国8省市支气管哮喘患者控制水平的流行病学调查[J].中华内科杂志，2014，53（8）：601-606.
[3] 欧阳晓平，吴峰，顾扬，等.沙美特罗替卡松联合苏黄止咳胶囊治疗咳嗽变异性哮喘疗效观察[J].临床肺科杂志，2013，18（2）：257-258.
[4] Bateman ED，Reddel HK，Eriksson G，et al. Overall asthma control：the relationship between current control and future risk [J]. J Allergy Clin Immunol，2010，3（125）：600-608.
[5] BaoW，Chen Q，Lin Y，et al. Efficacy of procaterol combined with inhaled budesonide for treatment of cough-variantasthma [J]. Respirology，2013，18（Suppl3）：53-61.
[6] Lai T，Wang S，Xu Z，et al. Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma：a systematic review and meta-analysis [J]. Sci Rep，2015，5（5）：8191.
[7] Terasakl G，Paauw DS. Evaluation and treatment of chronic cough [J]. Med Clin Nonh Am，2014，98（3）：39l-403.
[8] Weatherall M，Wijesinghe M，Perrin K，et al. Meta-analysis of the risk of mortality with salmeterol and the effect of concomitant inhaled corticosteroid therapy [J]. Thorax，2010， 65（1）：39-43.
[9] 中华医学会呼吸病学分会哮喘学组.咳嗽的诊断与治疗指南（2015）[J].中华结核和呼吸杂志，2016，39（5）：323-354.
[10] 郑兰芝，蒋旭宏，丁黎敏，等.苏黄止咳胶囊联合舒利迭治疗咳嗽变异性哮喘临床观察[J].中国中医急症，2014， 23（8）：1548-1549.
[11] 中华人民共和国卫生部.中药新药临床研究指导原则[M].北京：中国医药科技出版社，2002：26-28.
[12] 叶飒，严建平，王宏，等.咳嗽变异性哮喘患者诱导痰P物质与气道反应性的关系研究[J].实用医学杂志，2013， 29（16）：2605-2607.
[13] 熊宁，彭志群，吴金飞，等.苏黄止咳胶囊治疗咳嗽变异性哮喘的有效性研究[J].中国医药，2013，8（8）：107l-1072.
[14] 陈利玲，唐燕，黎晓莉.苏黄止咳胶囊治疗咳嗽变异性哮喘的疗效及对患者诱导痰中炎性介质的影响[J].河北医学，2015，21（10）：1602-1605.
[15] 刘伟.苏黄止咳胶囊对咳嗽变异性哮喘患者的疗效及免疫因子的影响[J].中国医学创新，2015，（26）：59-61，62.
[16] 刘敏，程发峰，王庆国，等.麻黄免疫调节作用研究进展[J].河北中医，2015，37（7）：1104-1106.
[17] 甘璐，徐娜，李茜.苏黄止咳胶囊治疗小儿咳嗽变异性哮喘临床观察[J].中国中医急症，2013，22（1）：138-139.
[18] 周洋，张家洪.苏黄止咳胶囊联合沙美特罗/丙酸氟替卡松对咳嗽变异性哮喘患者气道炎症的影响[J].实用医学杂志，2016，32（2）：298-299.
[19] 钟南山.支气管哮喘-基础与临床（精）[M].北京：人民卫生出版社，2006：885-886.
[20] 王四海.嗜酸粒细胞性支气管炎与咳嗽变异性哮喘患者的气道炎症特征的研究[J].临床和实验医学杂志，2013， 12（6）：416-417.
[21] 戴磊，黎伟林，黎志刚，等.中医药治疗咳嗽变异性哮喘随机对照试验的Meta分析[J].中国医学创新，2017，14（8）：21-27.
[22] 姜明明，韩雪梅，于明涛.布地奈德对支气管哮喘患儿血清IL-4、CKLF-1和IFN-γ水平的影响[J].中国现代医生，2017，55（4）：4-6.
[23] 胡钰.消咳喘胶囊治疗支气管哮喘急性发作期的疗效评价[J].实用临床医药杂志，2013，17（13）：94-96.
[24] 王玥.吸入小剂量沙美特罗/丙酸氟替卡松治疗咳嗽变异性哮喘的临床观察[J].中国医学创新，2013，（12）：119-120.
[25] 张涵，张家洪，马经平，等.苏黄止咳胶囊对支气管哮喘患者气道炎症及细胞免疫影响研究[J].中华肺部疾病杂志：电子版，2017，10（3）：344-346.